Drugs / RO7300490
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04857138 | May 2021 → Jan 2024 | cancer | Hoffmann-La Roche | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RO7300490 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04857138 ↗ |
| Action | Activate | “CD40 agonist” NCT04857138 ↗ |
| Route | Intravenous | “receive escalating doses of RO7300490 intravenously (IV)” NCT04857138 ↗ |
| Target | CD40 | “CD40 agonist” NCT04857138 ↗ |
| Target | FAP | “fibroblast activation protein (FAP)-targeted” PMID 42067656 ↗ May 2026 |